このアイテムのアクセス数: 0

このアイテムのファイル:
このアイテムは一定期間後に公開されます。
公開日については,アイテム画面の「著作権等」でご確認ください。
タイトル: 中高リスク筋層非浸潤性膀胱癌に対する抗癌剤術後即時単回膀胱内注入療法の再発予防効果
その他のタイトル: Post-Operative Immediate Single Instillation of Chemotherapy as Prevention of Recurrence after Transurethral Resection of Intermediate-High Risk Non-Muscle-Invasive Bladder Cancer
著者: 杉浦, 晋平  KAKEN_name
能登, 紀彰  KAKEN_name
小泉, 充之  KAKEN_name
高本, 大路  KAKEN_name
藤川, 直也  KAKEN_name
池田, 伊知郎  KAKEN_name
著者名の別形: Sugiura, Shimpei
Noto, Noriaki
Koizumi, Mitsuyuki
Takamoto, Daiji
Fujikawa, Naoya
Ikeda, Ichiro
キーワード: Bladder cancer
Intravesical chemotherapy
Immediate single instillation
発行日: 31-Jul-2018
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要 = Acta urologica Japonica
巻: 64
号: 7
開始ページ: 297
終了ページ: 301
抄録: We retrospectively evaluated the efficacy of immediate single instillation (SI) of pirarubicine hydrochloride (THP) in the chemoprevention of intermediate and high risk patients with non-muscle-invasive bladder cancer (NMIBC). The study population consisted of 256 intermediate and high risk patients with NMIBC who underwent Bacillus Calmette-Guerin (BCG) induction therapy or delayed intravesical chemotherapy between 1999 and 2014. We introduced SI of 30 mg THP in 30 ml normal saline for all cases in 2010, and thus earlier cases could be considered as historical controls. As BCG induction therapy, patients received 80 mg of BCG Tokyo strain 2 weeks after transurethral resection of bladder tumor (TURBT), and the instillations were repeated weekly for 8 weeks. On the other hand, as delayed intravesical chemotherapy, patients received 30 mg THP in 30 ml normal saline over a period of 6 months starting 2 weeks after TURBT. The instillation schedule was once a week for 1 month, every other week for 1 month and once a month for 4 months. The patients were followed with cystoscopy and urine cytology every 3 months for the first 2 years and every 6 months thereafter. The 3-, and 5-year non-recurrence rates were 80. 3 and 80.3%, respectively, in the single immediate instillation group and 69.7 and 64.5%, respectively, in the control group. Univariate analysis revealed a significant difference between the SI group and the control group (P=0. 025). Multivariate analysis showed that there was an independent and significant recurrence risk factor in selecting chemotherapy instead of BCG in additional intravesical instillation therapy and not to perform SI. Limitations of our study are its retrospective and nonrandomized nature with a limited number of patients.
著作権等: 許諾条件により本文は2019/08/01に公開
DOI: 10.14989/ActaUrolJap_64_7_297
URI: http://hdl.handle.net/2433/233803
PubMed ID: 30089338
出現コレクション:Vol.64 No.7

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。